0000950170-24-043014.txt : 20240409 0000950170-24-043014.hdr.sgml : 20240409 20240409163012 ACCESSION NUMBER: 0000950170-24-043014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240409 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viracta Therapeutics, Inc. CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943295878 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 24833087 BUSINESS ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 BUSINESS PHONE: 858-400-8470 MAIL ADDRESS: STREET 1: 2533 S COAST HWY 101 STREET 2: SUITE 210 CITY: CARDIFF STATE: CA ZIP: 92007 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 FORMER COMPANY: FORMER CONFORMED NAME: SUNESIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980501 8-K 1 virx-20240409.htm 8-K 8-K
0001061027falseViracta Therapeutics, Inc.00010610272024-04-092024-04-09

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 09, 2024

 

 

VIRACTA THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-51531

94-3295878

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2533 S. Coast Hwy. 101, Suite 210

 

Cardiff, California

 

92007

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 400-8470

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

VIRX

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01. Other Events

On April 9, 2024, Viracta Therapeutics, Inc. (the “Company”) received a written notice from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq's Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Select Market, as the closing bid price of the Company’s common stock had met or exceeded $1.00 per share for a minimum of ten consecutive business days and that the matter was now closed.

As previously disclosed on November 15, 2023, the Company received a written notice from Nasdaq indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Company had 180 calendar days, or until May 13, 2024, to regain compliance with the Minimum Bid Price Requirement.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Viracta Therapeutics, Inc

 

 

 

 

Date:

April 9, 2024

By:

/s/ Mark Rothera

 

 

 

Mark Rothera
President and Chief Executive Officer

 

 EX-101.SCH 2 virx-20240409.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information
Apr. 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 09, 2024
Entity Registrant Name Viracta Therapeutics, Inc.
Entity Central Index Key 0001061027
Entity Emerging Growth Company false
Entity File Number 000-51531
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3295878
Entity Address, Address Line One 2533 S. Coast Hwy. 101, Suite 210
Entity Address, City or Town Cardiff
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92007
City Area Code (858)
Local Phone Number 400-8470
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol VIRX
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,6#B5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #%@XE85/E8V.X K @ $0 &1O8U!R;W!S+V-O&ULS9)- M:L,P$$:O4K2W1[9+H,+Q)B6K% H-M'0GI$DB:OT@3;%S^\INXE#: Q2TT,9##=C;9W2:BP9B>B( "2.J&5JMJ7M\7/)^'?621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ,6#B5@28_Z>: 0 *X0 8 >&PO=V]R:W-H965T&UL MI9AO<^(V$,:_BL;M=.YF$FP9") ",X0D/>;N=OA"V#)K8EBO)(7S[ MK@RQ:6K6S/1-\!_MXY]6ZV?E#+=2/>L-YX:\)G&J1\[&F.S:=76PX0G3+9GQ M%.Y$4B7,P*E:NSI3G(5%4!*[ON==N0D3J3,>%M?F:CR4N8E%RN>*Z#Q)F-K= M\%AN1PYUWBX\BO7&V ON>)BQ-5]P\ULV5W#FEBJA2'BJA4R)XM'(F=#K&[]C M XH13X)O]=$QL5-92?EL3V;AR/$L$8]Y8*P$@Y\7/N5Q;)6 X^^#J%,^TP8> M'[^IWQ>3A\FLF.93&7\7H=F,G+Y#0AZQ/#:/],T$(@ M>R5D[QS(*>10L1A40_Y*/O-='2:NY'D>]:ZHY_<0K'Z)U3\'ZR[A:BW2-?D% MXLV&3&62L;06#M=KJK=!R34XA^M>Q)P\Y,F*JSH67 ,2==FEW39%>*A7V:EW M#A&4@U295(6)7I"%@9> 2 49RV%E88%E6%MZ#>JW=QCDD>?36>]47*&[DWY4PAJ>V$R1Y>G 174OU_SH"K5H"Q?U\(6,1"&/; MU%RD,-'89$>I_6'TD"Q[D4&^U^XT&)5N? MT-X61@;/L*7,F"(O+,XY^=%KV9T2R6#">L,4"EYU 1^W[:5BH2W Q2Y9R=KR M:Q!XFCW^CI%4IN_C!OV6,W+W&FQ8NN8G=[T-0@^3Q>WDUSHF]^CKTW[)?V5V MDZA)S"-0\EH]<&JU_SC>GQB9%1^D*VG@\[8XW' &)6<'P/U(2O-V8K]QRW]1 MC/\!4$L#!!0 ( ,6#B5B?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND M,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0& M@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&- M!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+ MY2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'D ML\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y M+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^ M7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM! M)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z M!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C M$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7 M,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( ,6#B5B7BKL

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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - virx-20240409.htm 8 virx-20240409.htm virx-20240409.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "virx-20240409.htm": { "nsprefix": "virx", "nsuri": "http://viracta.com/20240409", "dts": { "inline": { "local": [ "virx-20240409.htm" ] }, "schema": { "local": [ "virx-20240409.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_4ba080aa-b473-4651-9761-1692288e8662", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "virx-20240409.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4ba080aa-b473-4651-9761-1692288e8662", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "virx-20240409.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://viracta.com/20240409/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-24-043014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-043014-xbrl.zip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virx-20240409_htm.xml IDEA: XBRL DOCUMENT 0001061027 2024-04-09 2024-04-09 0001061027 false Viracta Therapeutics, Inc. 8-K 2024-04-09 DE 000-51531 94-3295878 2533 S. Coast Hwy. 101, Suite 210 Cardiff CA 92007 (858) 400-8470 false false false false Common Stock, par value $0.0001 per share VIRX NASDAQ false